TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 90 ° flexion pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of hyperchogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing of the epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Anti-antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events / serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects reporting at least one Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects reporting at least one Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: ISS score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rush Videotape Tic Rating Scale (mRVTRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of heart failure hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Subsidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of high PVAT attenuation coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-year peritoneal metastasis-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Collection of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood Oxygenation Level Dependent (BOLD) fMRI signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient's satisfaction with their voice - VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient's satisfaction with their voice - TWVQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient's satisfaction with their voice - VHI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brain Structural Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain Functional activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Best brain metastasis response rate (BMRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in serum interleukin-2 (IL-2) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects with treatment emergent AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in systemic inflammatory profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: quantification of IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of infants with oxygen measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endocrine hormones including AMH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants Attaining Minimal Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to dapagliflozin treatment discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of dapagliflozin treatment discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of dapagliflozin treatment discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Minimal knee flexion during the single support phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to 2.0 g/dL Increase in Hemoglobin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnostic performance of PSMA PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cough Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life (CQLQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life (LCQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjective Patient Pain Experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain Medication Usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effusion/swelling Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intra-abdominal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exercise-induced proteins in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Center of gravity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessor recommendation for match list position
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in functional physical condition
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in serum butyrate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Suicide Ideation - Self Report
Endpoint domain: Adverse events/effects
Primary endpoint: Suicide Ideation - Clinician Rated
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of in-hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: NRS pain scoring scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: periprocedural stroke
Endpoint domain: Mortality/survival
Primary endpoint: stroke ipsilateral to the procedure
Endpoint domain: Mortality/survival
Primary endpoint: Change in left ventricular efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functioning in musculoskeletal conditions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility of supervised adapted physical activity program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Access Site Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients achieving PASI 75 response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients achieving sPGA 0/1 with at least 2 points improvement from baseline at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Anxiety assessment using HAM-A
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression assessment using HDRS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perception of stress assessment using PSS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-endodontic pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Occurrence of Symptomatic PCR-Positive COVID-19 at 14 Days Post-booster Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: First Occurrence of Symptomatic PCR-Positive COVID-19 at 12 Months Post-booster Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemoprevention failure defined by qPCR positive parasites or malaria slide positive parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of antimalarial resistance markers among chemoprevention failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence over time of parasites with dhfr/dhps/pfcrt/pfmdr1 mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Accuracy of anterior nasal swab in rapid antigen tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for recovery of pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for recovery of PaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time for recovery of PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean psychomotor vigilance test reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal event-related potential (ERP) during initial learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Edinburgh Postnatal Depression Scale (EPDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the Impact of Fibromyalgia on Daily Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lower Limb Strength and Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedures without serious use error
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of NIs
Endpoint domain: Adverse events/effects
Primary endpoint: Driving Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: EEG characteristics of motor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving FDS Score of =0
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concentration of targeted bacterial species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Discrimination between benign and malignant adnexal masses (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification of adnexal masses as benign or malignant (Sensitivity, Specificity, PPV, NPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of individual risk of malignancy of adnexal masses (Calibration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes potentiation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional Status score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: BAECK PHYSICAL ACTIVITY QUESTIONNAIRE
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Scale for Assessment and Rating of Ataxia (SARA) modified total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Implant and prosthetic success
Endpoint domain: Mortality/survival
Primary endpoint: Implant and prosthetic survival
Endpoint domain: Mortality/survival
Primary endpoint: Hidradenitis Suppurativa Clinical Response 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Does Limiting Toxicity (DLT) rates
Endpoint domain: Adverse events/effects
Primary endpoint: Brief Fatigue Inventory (BFI) score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Identification of serum-protein markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Identification of immune cell profile-protein markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with response based on IWG-MRT criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POF rate
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability as measured by all adverse events related to DBS
Endpoint domain: Adverse events/effects
Primary endpoint: Opioid use assessed via quantitative urine toxicology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-operative edema/ecchymosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart coherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived quality of life and wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline on the Alzheimer's disease assessment scale-cognitive section (ADAS-Cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Whole body lipolysis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall abdominal symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in percent body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Percent Change From Baseline in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary protein changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rapid Upper Limb Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction regarding perception of care quality at Visit 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction regarding perception of care quality at Visit 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Three-dimensional changes of free gingival graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Atogepant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Ubrogepant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appetite level score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin tunnel
Endpoint domain: Adverse events/effects
Primary endpoint: Normalization of platelet count (≥150 x 10^9/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Normalization of LDH levels to below ULN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of Schistocyte levels (<1%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tumor progression and metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Memorial Anxiety Scale for Prostate Cancer (MAX-PC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Decisional Conflict Scale (DCS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Expanded Prostate Cancer Index Composite Short Form (EPIC-26)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in EuroQol-5 Dimension (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Primary imaging endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stone free rate: clinical
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stone free rate: imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of fetal brain anomalies with additional views
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of successfully included patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients in which follow-up procedures were fully adhered to
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of problems or barriers during pilot
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in Dryness/Scaling/Roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in Luminosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence and severity of treatment-emergent solicited local and systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of treatment-emergent unsolicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of treatment-emergent SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in cannabis use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in symptoms of cannabis use disorder (CUD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in generic quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average lesion fluorescence loss (ΔF%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface area of WSL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of WSL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACLs learning outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in percent accurate words in probe list
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percentage of Participants With Hemolysis Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in Percentage of Participants With Transfusion Avoidance (TA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in diet quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Inter-recti distance (IRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain glucose utilisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cortical network activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of range of motion prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDAC expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain response to stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in insulin resistance scores (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants who Achieve Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants who Achieve Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Hepatic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of study treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of study discontinuations due to treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Peanut specific/total IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Breast cancer specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in philtral column height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in philtral column projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia Severity Index (ISI) Change
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sedative-Hypnotic Medication Use Change
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Evidence of detection for any marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting-State Functional MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients who lack adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: grading of patch test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Death or stroke within 30 days of treatment or ipsilateral stroke or neurological death between 30 days and 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Complete occlusion of the aneurysm with Contour without retreatment, recurrent subarachnoid hemorrhage, or significant parent artery stenosis at one (1) year after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes